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Intravitreal  Triamcinolone  Reinjection  for  Refractory 
Diabetic  Macular  Edema
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Purpose: To evaluate the effect of intravitreal triamcinolone acetonide (IVT) reinjection on clinical and optical 
coherence tomographic features in refractory diabetic macular edema.
Methods: In a prospective interventional case series, all IVT treated patients enrolled in a previous clinical 
trial were recalled to have a new ophthalmologic examination and optical coherence tomography (OCT) 
performed. Eyes found suitable for reinjection received 4 mg IVT. Complete clinical examination and OCT 
were repeated at 2 and 4 months post-injection. The changes were statistically analyzed using a paired t test 
and were compared to the results of the first injections.
Results: Of all returning patients, 12 cases with complete records were considered candidates for 
reinjection. Visual acuity (VA) changes were not significant after the first and second interventions, although 
there was a relative improvement (0.14 logMAR) 2 months after the first injection. Reductions of central 
macular thickness (CMT) were 43±69 μm, and 40±69 μm after the first injection and 27±48 μm, 49±58 μm 
after the reinjection at 2 & 4 months, respectively. None of the mentioned changes was significant. After 
the second injection, however, intraocular pressure was elevated at both 2 & 4 months (3.6 & 2.4 mmHg 
respectively, P<0.05). Two months after the first administration, intraocular pressure was found to be raised 
significantly (5.58 mmHg, P=0.001). 
Conclusions: The transient beneficial effects of IVT on diabetic macular edema are not repeated with second 
injections. However, IVT-related ocular hypertension is more persistent after reinjection.  Korean Journal of 
Ophthalmology 20(3):156-161, 2006
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Macular edema is the most important manifestation of non- 
proliferative diabetic retinopathy and a predominant cause of 
legal blindness in diabetic patients. According to the early 
treatment of diabetic retinopathy study (ETDRS), the treat-
ment of choice for clinically significant macular edema 
(CSME) is laser therapy. However, some cases of CSME are 
refractory to laser therapy and do not have a good prognosis 
with such treatment.
1 
Recently, some promising results have been shown in 
different studies for the treatment of refractory diabetic 
macular edema with intravitreal triamcinolone acetonide 
(IVT).
2-5 However, the follow-up periods in these studies 
were rather short and there were only limited reports 
concerning reinjection in these cases. 
There is the possibility of a poor and/or transient response 
to the first administration, which would therefore require 
repeated injections. We performed a study on patients with 
diabetic macular edema who had already received one IVT 
injection. The purpose of this study was to discern both the 
long-term result of IVT in diabetic macular edema and, more 
importantly, the effect of reinjection on the eyes that were 
not completely improved.
Materials and Methods
In a prospective, interventional case series study, all of the 
patients in the treated group of a previous clinical trial who 
received one dose of 4 mg IVT for refractory diabetic 
macular edema were recalled for reexamination and reassess-
ment of macular thickness by optical coherence tomography 
(OCT-2, Zeiss, Dublin, CA) about 10 months after their first 
injections. Both the primary trial and this part of the study 
were approved by the Review Board/Ethics Committee of the 
Ophthalmic Research Center. 
The previous study included eyes meeting criteria for 
CSME based on the ETDRS definition, with an anticipated RAMEZANI  A,  et  al.  TRIAMCINOLONE  REINJECTION  FOR  MACULA  EDEMA
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CMT  changes  (μ m) P  value
Month  0  to  2
Month  2  to  4
Month  0  to  4
Month  0  to  recall
Month  2  to  recall
Month  4  to  recall
-107±158
+92±109
 - 4 0 ±202
 - 2 1 ±187
+122±139
 + 9 ±137
0.013
0.004
0.386
0.614
0.003
0.782
+&-  Signs  imply  increase  and  decrease  in  CMT,  respectively.
Table 1. Changes  of  central  macular  thickness  (CMT) 
between  months  0,  2,  4,  and  the  time  of  recall  (paired  t 
test)
Fig. 1. Mean visual acuity (SD) before, 2, 4 and about 10 months 
after  the  first  intravitreal  triamcinolone  injection. 
unfavorable visual outcome after initial or supplemental 
macular photocoagulation due to one or more of the follo-
wing findings: 1- macular ischemia, 2- visual acuity (VA) ≤
20/200, 3- diffuse macular edema, 4- severe hard exudates 
(HE) accumulation in the fovea, and 5- lack of response to 
previous laser photocoagulations with the last one being more 
than 3 months before. The patients were randomly assigned 
to the treatment (4 mg IVT) and placebo groups.
In the current study, all of the IVT-received patients in the 
initial part were recalled for a new clinical and tomographic 
evaluation. IVT reinjection was planned for all patients 
except for those who met the following criteria: (1) history 
of intraocular pressure (IOP) more than 30 mmHg after the 
first injection, (2) intraocular operation after the first 
injection, (3) VA ≥20/50, (4) IOP >21 mmHg and/or taking 
antiglaucoma medication at the time of reexamination, (5) 
lens opacity severe enough to interfere with visual acuity 
testing and performing OCT, (6) central macular thickness 
(CMT) less than 200 μ m  measured by OCT, (7) being 
candidate for intraocular surgery, (8) one-eyed patients, and 
(9) Non-compliance.
Injections were done under sterile conditions in the 
operating room with topical anesthesia and insertion of a lid 
speculum. Four milligrams (0.1 cc) triamcinolone acetonide 
(Kenacort) was injected intravitreally with a 27-gauge needle 
through the superotemporal quadrant. IOP was checked about 
10 minutes after injection with a Goldman applanation tono-
meter and anterior chamber paracentesis was performed if 
IOP exceeded 30 mmHg.
Examinations were performed at 2 and 4 weeks after 
injection to monitor IOP and complications. In eyes with IOP 
>21 mmHg, timolol was prescribed twice daily, and in 
refractory cases, one drop of dorzolamide three times a day 
was added. 
Complete ophthalmic examination and OCT were repeated 
2 and 4 months after the second injections in an attempt to 
replicate the follow-up periods after the primary injections in 
the first part of the study. 
Statistical analysis was performed using paired t and 
independent sample t tests for evaluating quantitative variable 
changes within and between injections, respectively. P values 
<0.05 were considered statistically significant. Data were 
analyzed using SPSS 11.5. 
Results
The results are presented in two parts: first, the long-term 
follow-up results comparing the findings of the new exams 
with the previous data, and second, the results of intravitreal 
triamcinolone reinjection in cases who met the criteria for 
this intervention. 
Of 45 patients who were in the treated group of the first 
part of the study, 23 (14 male, 9 female) returned for reevalu-
ation. To asses whether these 23 patients could represent all 
of the cases, their previous data were compared with those 
of the remaining 22 patients who did not return for new 
examination. In this manner, it was confirmed that there was 
no significant difference in the effect of IVT in the first part 
of the study with respect to VA, CMT, and IOP between 
these two groups of patients (data are not shown).
1. Long-term follow up results
The mean time interval between the first injection and the 
new examination was 10.87±2.1 months (range: 8 to 18 
months). 
The comparison of VA changes between the new exam 
and each previous one (at months 0, 2, and 4 after the first 
injection) were not statistically significant. Fig. 1 demon-
strates that VA remained relatively stable during 10 months 
of follow up. However, a transient but statistically insignifi-
cant improvement occurred by 2 months after the injection. 
The assessment of CMT between the early phases and the 
time of recall are presented in Table 1. Paired t test shows 
statistically significant changes between months 0 and 2, 
months 2 and 4, and month 2 and the time of recall. Fig. 
2 shows a transient reduction of CMT which occurred at 2 
months post-injection and a steady thickness level from 
month 4 until month 10. 
After a rise at 2 months, IOP decreased toward the normal 
level but did not return to its preinjection level (Fig 3). 
Comparison of the means of IOP (Table 2) confirmed the 
presence of a significant difference between IOP at 10 Korean  J  Ophthalmol  Vol.20,  No.3,  2006
158
Fig. 2. Mean central macular thickness before, 2, 4 and about 10 
months  after  the  first  intravitreal  triamcinolone  injection. 
Fig. 3. Mean  intraocular  pressure  before,  2,  4  and  about  10 
months  after  the  first  intravitreal  triamcinolone  injection. 
IOP  changes  (mmHg) P  value
Month  0  to  2
Month  2  to  4
Month  0  to  recall
Month  4  to  recall
+5.43±5.8
-3.74±7.3
+1.96±2.6
+0.26±4.2
<0.001
0.018
0.002
0.766
+&-  Signs  imply  increase  and  decrease  in  IOP,  respectively.
Table 2. Changes  of  intraocular  pressure  (IOP)  between 
months  0,  2,  4,  and  the  time  of  recall  (paired  t  test)
months post-injection compared to pre-injection levels (P= 
0.002). 
2. Results of reinjection
Eight of 23 returned cases (34.8%) were not candidates for 
reinjection of IVT for the following reasons: history of IOP 
>30 mmHg after the first injection, VA >20/50, IOP >20 
mmHg, vitreous hemorrhage (two cases), and CMT <200 μ m 
Another patient developed ocular hypertension after the 
firstintervention which persisted and necessitated long-term 
Fig. 4. V i s u a l  a c u i t y  c h a n g e s  ( S D )  a f t e r  t h e  f i r s t  a n d  t h e  s e c o n d  
injections. 
Fig. 5. Central  macular  thickness  changes  after  the  first  and  the 
second  injections. 
antiglaucoma medication. Non-compliance was the cause of 
the last excluded case. 
Fifteen patients received reinjection of IVT without signifi-
cant complications. Two of them were lost to follow-up and 
one was excluded because of cataract progression. Therefore, 
statistical analyses were performed on 12 eyes. 
Evaluation of VA differences between the first and the 
second injection is shown in Fig. 4. Pretreatment visual 
acuity of the second intervention was better than that of the 
first, but these findings were not statistically significant 
(P=0.40). Although the comparisons of VA changes between 
and within the two injections did not show a statistically 
significant difference (Table 3), its improvement (0.14 RAMEZANI  A,  et  al.  TRIAMCINOLONE  REINJECTION  FOR  MACULA  EDEMA
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Month
1st  injection 2nd  injection
P  value
between  periods IOP  changes 
(mmHg)
P  value
within  period
IOP  changes 
(mmHg)
P  value
within  period
0  to  2
2  to  4
0  to  4
+5.58±4.4
-4.75±3.3
+0.83±3.3
0.001
<0.001
0.400
+3.58±4.6
+0.67±4.7
+2.44±2.7
0.021
0.681
0.028
0.291
0.006
0.250
+&-  Signs  imply  increase  and  decrease  in  IOP,  respectively.
Table 5. Intraocular  pressure  (IOP)  changes  following  the  first  and  the  second  IVT  injections  in  a  group  of  cases  with 
diabetic  macular  edema  (paired  t  and  independent  sample  t  tests f o r  c h a n g e s  w i t h i n  a n d  b e t w een  periods,  respectively). 
Month
1st  injection 2nd  injection
P  value
between  periods CMT  changes
(μ m)
P  value
within  period
CMT  changes
(μ m)
P  value
within  period
0  to  2
2  to  4
0  to  4
-43±185
+102±100
-40±217
0.558
0.036
0.571
-27±152
+11±65
+49±152
0.591
0.686
0.430
0.843
0.085
0.931
+&-  Signs  imply  increase  and  decrease  in  CMT,  respectively.
Table 4. Central  macular  thickness  (CMT)  changes  following  the  first  and  the  second  IVT  injections  in  a  particular 
group  of  cases  with  diabetic  macu l a r  e d e m a  ( p a i r e d  t  a n d  i n d e p e ndent  sample  t  tests  for  changes  within  and  between 
periods,  respectively) 
Month
1st  injection 2nd  injection
P  value
between  periods VA  changes 
(logMAR)
P  value
within  period
VA  changes 
(logMAR)
P  value
within  period
0  to  2
2  to  4
0  to  4
-0.14±0.38
+0.10±0.25
-0.03±0.35
0.229
0.212
0.799
+0.08±0.28
-0.01±0.35
+0.09±0.20
0.328
0.930
0.193
0.117
0.414
0.362
+&-  Signs  imply  increase  and  decrease  in  logMAR  notation  that  means  decrease  and  increase  in  VA,  respectively.
Table 3. Vis ual acuit y (VA) changes  fo llowing the first  and the seco nd IVT injections in a group  of  cases with diabetic 
macular  edema  (paired  t  and  independent  sample  t  tests  for  changes  within  and  between  periods,  respectively).
Fig. 6. I n t r a o c u l a r  p r e s s u r e  c h a n g e s  a f t e r  t h e  f i r s t  a n d  t h e  s e c o n d 
injections. 
logMAR) at 2 months following the first injection was not 
repeated after the second one. 
Baseline CMT was 388 and 378 microns before the first 
and the second injections respectively (P=0.89). Although not 
statistically significant, mean CMT reduction after the 
primary injection (43 μm) was greater than that of the rein-
jection (27 μm). Comparisons of thickness variations within 
and between the two injections did not show a significant 
difference except in one stage. As shown in Table 4, the 
thickness changes between 2 and 4 months following the first 
injection was significant (102 μm, P=0.036), which confirmed 
the reduction of IVT effect. Fig. 5 represents similar 
responses of macular thickness to each injection. 
Mean initial IOP before the second injection was higher 
than that of the first one (P=0.037). Table 5 indicates that 
IOP rise after the first intervention (5.58 mmHg) was greater 
than that following the reinjection (3.58 mmHg); however, it Korean  J  Ophthalmol  Vol.20,  No.3,  2006
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persisted longer after the repeated injection (Fig. 6). The IOP 
changes between months 2 and 4 were -4.75 and +0.66 
mmHg after the first and the second injections, respectively, 
and showed significant difference (P=0.006).
Discussion
According to the results, one can reach the following 
conclusions:
1. In diabetic patients, the first IVT injection induces relative 
VA improvement and macular thickness reduction at 2 
months. These variables return to their initial levels by 4 
months and thereafter remain stable until month 10. 
2. The second IVT injection is not as effective as the first 
one. 
3. Significant increase of IOP at month 2 normalizes by 
month 4 but does not return to its previous level even 
after 10 months of follow up.
4. IOP rise after reinjection is more refractory to treatment 
and does not decrease as rapidly as after the first adminis-
tration. 
Only about half of the patients returned for reevaluation. 
This would raise the possibility of a selection bias in this 
study. The reason for seeking additional medical care could 
imply that these patients were either good or poor responders 
to the primary IVT injection. To evaluate this possibility, we 
compared their previous data and it was shown that both 
returned and unreturned patients had similar responses to the 
primary IVT.
The long-term effect of IVT on diabetic macular edema is 
not well known. The mean follow up duration in the Jonas 
et al.
6 study was 13.2±6.0 months. However, the records were 
completed for only 7 and 5 patients until 10 and 12 months, 
respectively. In their study, following the injection of 20-25 
mg IVT, visual acuities reached a plateau level at 1-7 months 
and returned to initial levels after 8-9 months. The authors 
stated that there was a 7 to 8-month effect time for mega 
dose IVT in the management of diabetic macular edema. 
Two-line improvement of VA by months 5 and 7 in 40% and 
54% of the eyes respectively were significant.
2,7 The longer 
drug effect in these two study groups (6 and 7 months) in 
relation to that of ours may be the result of the higher drug 
dosage. 
Similar to our study, Martidis
3 and Ciardella
4 showed that 
the maximum effect of 4 mg IVT on macular thickness 
occurred between 1 to 3 months. Due to recurrences, a few 
cases in these two studies received repeated injection. 
Ocular hypertension is a familiar complication of IVT. 
However, before this study, the persistence of pressure above 
its initial level up to 10 months after injection had not been 
shown. In a few studies, the percentage of patients who 
developed IVT-related ocular hypertension were reported, but 
no comparison was performed between the first and the last 
mean IOP.
3,5 Martidis el al.
3 showed a 1.9-mmHg rise of the 
mean IOP in 8 patients for 6 months, which was comparable 
to the 1.96 mmHg in 23 cases of our study. Significant 
persistence of ocular hypertension for 5 and 6 months was 
also stated in two articles by Jonas.
2,7 According to another 
of studies which was comparable to ours, the elevation of 
IOP was significant at 3 months and took 8-9 months to 
return to its previous level.
8 In all mentioned studies, the 
reported means of IOP at each visit and the calculated time 
for their elevations were in spite of taking antiglaucoma 
medication. As with our findings, these studies stressed the 
long term effect of IVT on IOP. 
We are unaware of any study that has been published with 
the stated purpose of evaluating the effect of IVT reinjection 
in diabetic macular edema. Three patients in the Martidis’ et 
al.
3 study received repeated injection, but the results were not 
reported. 
In Ciardella’s
4 study, the second injection of IVT was 
performed for 12 eyes with 2- to 11-month (mean 5.7±2.6) 
intervals between the two injections. Mean VA increased 
form 0.27±0.15 to 0.42±0.25 one month after the reinjection. 
Mean macular thickness reduced from 463±115 μm to 
213±63 μm. However, it was not stated whether this amount 
of reduction was specific to these 12 eyes or not. 
To our knowledge, our study was the first report regarding 
the results of two IVT injections that were performed using 
the same time intervals for cases with diabetic macular 
edema. In this study, the changes of VA, CMT, and IOP after 
the second injection were compared to the changes of these 
variables that occurred in the same eyes within similar phases 
after the first injection. 
According to the present study and other published data, 
the therapeutic effect of IVT does not last for 10 months. 
Therefore, we may conclude that the changes after the 
reinjection are independent of the long-lasting effect of 
primary IVT. To confirm this assumption, we refer to Beer's
9 
article in which the measurable amount of triamcinolone in 
non-vitrectomized eyes was found until 93±28 days after 
injection. It should be noticed, however, that there is a report 
about the persistence of IVT after 1.5 years, but this occurred 
following 20-25 mg of drug injection.
10 
Initial mean VA in our 12 eyes before the primary injec-
tion (0.93 logMAR) was lower than that before the secondary 
injection (0.79 logMAR). This might be the reason for 
detecting more improvement in VA following the first 
intervention. Mean VA after the reinjection not only showed 
no improvement but even some worsening. 
CMT reduction was observed after both of the injections. 
Although these changes were not statistically significant, the 
reduction was more pronounced at month 2 after the initial 
injection. 
One of the limitations in our study was the low number 
of cases who received both injections. This might have 
decreased the power of the study to detect a difference 
following the two interventions. In spite of this limitation, the 
difference in the pattern of IOP changes between the two 
injections was significant. This study showed that repeated RAMEZANI  A,  et  al.  TRIAMCINOLONE  REINJECTION  FOR  MACULA  EDEMA
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injection (even after 10 months) had an additive effect on 
IOP. After reaching a maximum level at 2 months following 
both injections, IOP decreased to its previous level after the 
second injection but this effect was less pronounced than the 
first one. Considering that IVT does not remain effective in 
the eye for more than 10 months,
9 it might be suggested that 
a long-lasting or even irreversible effect of the drug on the 
anterior chamber angle component may be the reason for 
persistently increased IOP levels. This observation is not 
unexpected considering the side effects observed with other 
routes of corticosteroid administrations. In this method, 
however, a highly potent corticosteroid is in persistent contact 
with the anterior chamber angle with no major barrier like 
the cornea or sclera. 
No definitive cause could be discerned for the lower 
therapeutic effect after the reinjection. It has been found that 
the vitreous concentration of triamcinolone after 4-mg 
injection is 10,000 times greater than that required to occupy 
all of the corticosteroid receptors.
11 Therefore, the lower 
response to repeated rejections might be due in part to 
receptor down-regulation following this high dosage because 
of decreased affinity and/or number of receptors. Another 
hypothesis could be the worsening of macular edema during 
10 months of follow-up. 
Considering the greater adverse effects and slightly lower 
therapeutic response following the second administration, we 
would not recommend repeated IVT injections for diabetic 
macular edema as a routine treatment strategy. However, the 
number of cases in this report is rather low and comple-
mentary studies are suggested. 
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